Cargando…
Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
BACKGROUND: We tested the hypothesis that a novel vaccine developed from autologous dendritic cells (DC) loaded with cells from a unique allogeneic brain tumor cell line (GBM6-AD) would be well-tolerated and would generate an immune response. METHOD: Patients with recurrent primary brain tumors unde...
Autores principales: | Olin, Michael R, Low, Walter, McKenna, David H, Haines, Stephen J, Dahlheimer, Tambra, Nascene, David, Gustafson, Michael P, Dietz, Allan B, Clark, H Brent, Chen, Wei, Blazar, Bruce, Ohlfest, John R, Moertel, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019901/ https://www.ncbi.nlm.nih.gov/pubmed/24829761 http://dx.doi.org/10.1186/2051-1426-2-4 |
Ejemplares similares
-
Novel strategy for manufacturing autologous dendritic cell/allogeneic tumor lysate vaccines for glioblastoma
por: Parney, Ian F, et al.
Publicado: (2020) -
Therapeutic vaccines for malignant brain tumors
por: Gustafson, Michael P, et al.
Publicado: (2008) -
TRLS-09. USE OF A PAN-PEPTIDE CHECKPOINT INHIBITOR IN THE TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2023) -
Autonomic Cross-Innervation in Patients With Neurofibromatosis Type 2: Frey
Syndrome and Unilateral Epiphora With Rhinorrhea
por: Evans, Erica, et al.
Publicado: (2019) -
IMMU-10. USE OF A SINGLE PEPTIDE CHECKPOINT INHIBITOR FOR TREATMENT OF CENTRAL NERVOUS SYSTEM TUMORS
por: Moertel, Christopher, et al.
Publicado: (2021)